Karri Stark
YOU?
Author Swipe
View article: Data from Phase 0 Trial of AZD1775 in First-Recurrence Glioblastoma Patients
Data from Phase 0 Trial of AZD1775 in First-Recurrence Glioblastoma Patients Open
Purpose: AZD1775 is a first-in-class Wee1 inhibitor with dual function as a DNA damage sensitizer and cytotoxic agent. A phase I study of AZD1775 for solid tumors suggested activity against brain tumors, but a preclinical study indi…
View article: Supplementary Figures and Tables from Phase 0 Trial of AZD1775 in First-Recurrence Glioblastoma Patients
Supplementary Figures and Tables from Phase 0 Trial of AZD1775 in First-Recurrence Glioblastoma Patients Open
Supplementary Figures and Tables
View article: Data from Phase 0 Trial of AZD1775 in First-Recurrence Glioblastoma Patients
Data from Phase 0 Trial of AZD1775 in First-Recurrence Glioblastoma Patients Open
Purpose: AZD1775 is a first-in-class Wee1 inhibitor with dual function as a DNA damage sensitizer and cytotoxic agent. A phase I study of AZD1775 for solid tumors suggested activity against brain tumors, but a preclinical study indi…
View article: Supplementary Figures and Tables from Phase 0 Trial of AZD1775 in First-Recurrence Glioblastoma Patients
Supplementary Figures and Tables from Phase 0 Trial of AZD1775 in First-Recurrence Glioblastoma Patients Open
Supplementary Figures and Tables
View article: Supplementary Figure Legends from Phase 0 Trial of AZD1775 in First-Recurrence Glioblastoma Patients
Supplementary Figure Legends from Phase 0 Trial of AZD1775 in First-Recurrence Glioblastoma Patients Open
Supplementary Figure Legends
View article: Supplementary Data from Biomarkers and Bone Imaging Dynamics Associated with Clinical Outcomes of Oral Cabozantinib Therapy in Metastatic Castrate-Resistant Prostate Cancer
Supplementary Data from Biomarkers and Bone Imaging Dynamics Associated with Clinical Outcomes of Oral Cabozantinib Therapy in Metastatic Castrate-Resistant Prostate Cancer Open
Table S1. Baseline patient characteristics Table S2 Rank Correlations of Percent Change in Imaging with Percent Change in Bone Markers
View article: Data from Biomarkers and Bone Imaging Dynamics Associated with Clinical Outcomes of Oral Cabozantinib Therapy in Metastatic Castrate-Resistant Prostate Cancer
Data from Biomarkers and Bone Imaging Dynamics Associated with Clinical Outcomes of Oral Cabozantinib Therapy in Metastatic Castrate-Resistant Prostate Cancer Open
Purpose:Cabozantinib is a multitargeted tyrosine kinase inhibitor that demonstrated remarkable responses on bone scan in metastatic prostate cancer. Randomized trials failed to demonstrate statistically significant overall survival (OS). W…
View article: Supplementary Data from Biomarkers and Bone Imaging Dynamics Associated with Clinical Outcomes of Oral Cabozantinib Therapy in Metastatic Castrate-Resistant Prostate Cancer
Supplementary Data from Biomarkers and Bone Imaging Dynamics Associated with Clinical Outcomes of Oral Cabozantinib Therapy in Metastatic Castrate-Resistant Prostate Cancer Open
Table S1. Baseline patient characteristics Table S2 Rank Correlations of Percent Change in Imaging with Percent Change in Bone Markers
View article: Supplementary Figure Legends from Phase 0 Trial of AZD1775 in First-Recurrence Glioblastoma Patients
Supplementary Figure Legends from Phase 0 Trial of AZD1775 in First-Recurrence Glioblastoma Patients Open
Supplementary Figure Legends
View article: Data from Biomarkers and Bone Imaging Dynamics Associated with Clinical Outcomes of Oral Cabozantinib Therapy in Metastatic Castrate-Resistant Prostate Cancer
Data from Biomarkers and Bone Imaging Dynamics Associated with Clinical Outcomes of Oral Cabozantinib Therapy in Metastatic Castrate-Resistant Prostate Cancer Open
Purpose:Cabozantinib is a multitargeted tyrosine kinase inhibitor that demonstrated remarkable responses on bone scan in metastatic prostate cancer. Randomized trials failed to demonstrate statistically significant overall survival (OS). W…
View article: Phase I Trial of the Combination of Docetaxel, Prednisone, and Pasireotide in Metastatic Castrate-Resistant Prostate Cancer
Phase I Trial of the Combination of Docetaxel, Prednisone, and Pasireotide in Metastatic Castrate-Resistant Prostate Cancer Open
View article: Phase II Trial of Carboplatin, Everolimus, and Prednisone in Metastatic Castration-resistant Prostate Cancer Pretreated With Docetaxel Chemotherapy: A Prostate Cancer Clinical Trial Consortium Study
Phase II Trial of Carboplatin, Everolimus, and Prednisone in Metastatic Castration-resistant Prostate Cancer Pretreated With Docetaxel Chemotherapy: A Prostate Cancer Clinical Trial Consortium Study Open
View article: Protein Expression of DNA Damage Repair Proteins Dictates Response to Topoisomerase and PARP Inhibitors in Triple-Negative Breast Cancer
Protein Expression of DNA Damage Repair Proteins Dictates Response to Topoisomerase and PARP Inhibitors in Triple-Negative Breast Cancer Open
Patients with metastatic triple-negative breast cancer (TNBC) have a poor prognosis. New approaches for the treatment of TNBC are needed to improve patient survival. The concept of synthetic lethality, brought about by inactivating complem…